AVIR - CIK 0001593899
Atea Pharmaceuticals, Inc. has filed 301 documents with the SEC between 2013 and 2026. The most frequent type is insider trade (98 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| Insider trade (amended) | 4/A | 2026-05-21 | 2026-05-18 |
| Insider trade | 4 | 2026-05-20 | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-12 | 2026-03-31 |
| Major company event | 8-K | 2026-05-12 | 2026-05-12 |
| SCHEDULE 13G/A | - | 2026-05-06 | - |
| Proxy materials | DEFA14A | 2026-04-27 | - |
| Proxy statement | DEF 14A | 2026-04-27 | 2026-06-18 |
| SCHEDULE 13G/A | - | 2026-03-26 | - |
| Insider trade | 4 | 2026-03-13 | 2026-03-11 |
| Annual report | 10-K | 2026-03-05 | 2025-12-31 |
| Major company event | 8-K | 2026-03-05 | 2026-03-05 |
| SCHEDULE 13G | - | 2026-02-09 | - |
| Insider trade | 4 | 2026-02-03 | 2026-01-31 |
| Insider trade | 4 | 2026-02-03 | 2026-01-31 |
| Insider trade | 4 | 2026-02-03 | 2026-01-31 |
| Insider trade | 4 | 2026-02-03 | 2026-01-31 |
| Insider trade | 4 | 2026-02-03 | 2026-01-31 |
| Insider trade | 4 | 2026-02-03 | 2026-01-31 |
| Major company event | 8-K | 2026-01-08 | 2026-01-08 |
| SCHEDULE 13G/A | - | 2025-12-05 | - |
| Quarterly report | 10-Q | 2025-11-12 | 2025-09-30 |
| Major company event | 8-K | 2025-11-12 | 2025-11-12 |
| Employee stock plan | S-8 | 2025-08-07 | - |
| Major company event | 8-K | 2025-08-07 | 2025-08-07 |
| Quarterly report | 10-Q | 2025-08-07 | 2025-06-30 |
| SCHEDULE 13G/A | - | 2025-08-06 | - |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| Insider trade | 4 | 2025-06-24 | 2025-06-20 |
| New insider ownership | 3 | 2025-06-24 | 2025-06-20 |
| Major company event | 8-K | 2025-06-20 | 2025-06-20 |
| SCHEDULE 13G/A | - | 2025-05-14 | - |
| Major company event | 8-K | 2025-05-12 | 2025-05-12 |
| Quarterly report | 10-Q | 2025-05-12 | 2025-03-31 |
| Proxy statement | DEF 14A | 2025-04-29 | 2025-06-20 |
| SCHEDULE 13G/A | - | 2025-04-23 | - |
| Major company event | 8-K | 2025-04-17 | 2025-04-16 |
| SCHEDULE 13D/A | - | 2025-04-17 | - |
| Proxy materials | DEFA14A | 2025-04-03 | - |
| Proxy materials | DEFA14A | 2025-04-01 | - |
| Major company event | 8-K | 2025-04-01 | 2025-03-31 |
| Proxy materials | DEFA14A | 2025-03-26 | - |
| DFAN14A | - | 2025-03-26 | - |
| Proxy materials | DEFA14A | 2025-03-24 | - |
| Major company event | 8-K | 2025-03-24 | 2025-03-21 |
| SCHEDULE 13D/A | - | 2025-03-21 | - |